Ajay K. Singh, MBBS, FRCP, MBA

Articles by Ajay K. Singh, MBBS, FRCP, MBA

Ajay K. Singh, MBBS, FRCP, MBANKF Spring Clinical Meetings 2024 | May 23, 2024
Ajay K. Singh discussed his findings on daprodustat dosing and utilization of finerenone.
View More
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | April 12, 2024
APRIL has emerged as a critical factor in the pathogenesis of IgAN and is the focus of several clinical development programs.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | February 8, 2024
The benefit-risk ratio and considerations about unmet need are worth considering.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | February 5, 2024
SGLT2i therapy is contraindicated in patients with type 1 diabetes mellitus (T1DM) who have CKD.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | February 5, 2024
The first part of the dialysis moonshot is to prevent the need for dialysis.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | February 5, 2024
Measuring eGFR and UACR is a key component of guideline-directed medical therapy for patients with CKD from type 2 diabetes.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | February 5, 2024
The most important patients who should receive treatment with SGLT2 inhibitors are those with CKD and type 2 diabetes.
Ajay K. Singh, MBBS, FRCP, MBAFrom the Chair | August 28, 2023
Editor's Note: ...